Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • ASCI Milestone Awards
    • Video Abstracts
    • Conversations with Giants in Medicine
  • Reviews
    • View all reviews ...
    • The cGAS-STING pathway: DNA sensing in health and disease (Jun 2026)
    • Neurodegeneration (Mar 2026)
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • ASCI Milestone Awards
  • Video Abstracts
  • Conversations with Giants in Medicine
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
The LD78β isoform of MIP-1α is the most potent CCR5 agonist and HIV-1–inhibiting chemokine
Patricia Menten, Sofie Struyf, Evemie Schutyser, Anja Wuyts, Erik De Clercq, Dominique Schols, Paul Proost, Jo Van Damme
Patricia Menten, Sofie Struyf, Evemie Schutyser, Anja Wuyts, Erik De Clercq, Dominique Schols, Paul Proost, Jo Van Damme
View: Text | PDF
Rapid Publication

The LD78β isoform of MIP-1α is the most potent CCR5 agonist and HIV-1–inhibiting chemokine

  • Text
  • PDF
Abstract

LD78α and LD78β are 2 highly related nonallelic genes that code for different isoforms of the human CC chemokine macrophage inflammatory protein-1α (MIP-1α). Two molecular forms of natural LD78β (7.778 and 7.793 kDa) were identified from conditioned media of stimulated peripheral blood mononuclear cells. Although LD78α and LD78β only differ in 3 amino acids, both LD78β variants were 100-fold more potent chemoattractants for mouse lymphocytes than was LD78α. On the contrary, LD78β was only 2-fold more efficient than LD78α in chemoattracting human lymphocytes and monocytes. Using CC chemokine receptor–transfected cells, both molecular forms of LD78β proved to be much more potent than LD78α in inducing an intracellular calcium rise through CCR5. Compared with LD78α and RANTES, this preferential binding of LD78β to CCR5 resulted in a 10- to 50-fold higher potency in inhibiting infection of peripheral blood mononuclear cells by CCR5-using (R5) HIV-1 strains. To date, LD78β is the most potent chemokine for inhibiting HIV-1 infection, and can be considered as a potentially important drug candidate for the treatment of infection with R5 HIV-1 strains.

Authors

Patricia Menten, Sofie Struyf, Evemie Schutyser, Anja Wuyts, Erik De Clercq, Dominique Schols, Paul Proost, Jo Van Damme

×

Figure 4

Options: View larger image (or click on image) Download as PowerPoint
Inhibition of R5 HIV-1 infection by LD78β. PBMCs were protected from inf...
Inhibition of R5 HIV-1 infection by LD78β. PBMCs were protected from infection with the R5 BaL strain by the CC chemokines LD78α (filled circles), 7.778-Da LD78β (filled diamonds), 7.793-kDa LD78β (open diamonds), or RANTES (open circles). HIV-1 inhibition was evaluated by measuring viral p24 core antigen. Results at left show 1 representative experiment out of 2, whereas the results at right represent the mean ± SEM of 4 independent experiments.

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts